Astute Clinician Lecture
This annual lecture, begun in 1998 and part of the Wednesday Afternoon Lecture Series, honors a U.S. scientist who has observed an unusual occurrence, and by investigating it, has opened an important new avenue of research. The lectureship exemplifies how astute clinical observations can lead to innovative research. Speakers are proposed by members of the Medical Executive Committee (MEC) with voting for the top three candidates. Selection from this slate of candidates is made by the NIH Director.
Dr. Brigitte Widemann is a pediatric oncologist with the primary interest of developing effective therapies for children and adults with genetic tumor predisposition syndromes, such as neurofibromatosis type 1 (NF1), and rare solid tumors through innovative clinical trial design. Dr. Widemann currently serves as the head of the Pharmacology & Experimental Therapeutics Section and as Chief of NCI’s Pediatric Oncology Branch. Anticancer drug discovery and development are moving towards a more rational and targeted approach.
Dr. Ellen Sidransky is the Branch Chief of the Medical Genetics Branch and is a pediatrician and geneticist in the National Human Genome Research Institute at National Institutes of Health (NIH). Her research interests include both clinical and basic aspects of Gaucher disease and Parkinson disease, studies of genotype/phenotype correlation and genetic modifiers, insights from mouse models, and novel treatment strategies. She played a lead role in establishing the association between glucocerebrosidase and parkinsonism.
Age-related macular degeneration (AMD) is the leading cause of blindness in the United States and in the developed world. Two NIH-supported randomized clinical trials with 10 years of follow-up in nearly 10,000 participants demonstrated that nutritional supplements with antioxidant vitamins and minerals reduces the risk of progression to late AMD.
Dr. Gahl studies the natural history, diagnosis, and treatment of rare genetic disorders such as cystinosis, Hermansky-Pudlak Syndrome, sialic acid storage diseases, GNE myopathy, and disorders of platelets and pigmentation. He also investigates undiagnosed disorders under the aegis of the NIH Undiagnosed Diseases Program and Network, and pursues new disease discovery.
Dr. Abel's current research interests focus on elucidating the molecular mechanisms leading to cardiac dysfunction in diabetes and the regulation of myocardial growth and metabolism by insulin signaling.
Dr. Ronald Falk is internationally recognized physician-scientist whose lifelong career has been the study of autoimmune kidney disease and ANCA vasculitis. For over three decades, his research has led to a deeper understanding of the causes and conditions that may lead to the development of ANCA vasculitis in an effort to improve the lives of those patients afflicted with vasculitis and autoimmune kidney diseases.
Dr. Zarate's current research focus is on developing novel medications for treatment-resistant depression and bipolar disorder. His areas of expertise include biological and pharmacological aspects of mood disorders in adults. Dr. Zarate's group conducts proof-of-concept studies utilizing novel compounds and biomarkers (magnetoencephalography [MEG] and polysomnography [PSG], positron emission tomography, functional MRI and magnetic resonance spectroscopy [MRS]) to identify potentially relevant drug targets and biosignatures of treatment response.
The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.
Dr. Linehan has had a long-standing interest in identification of the genetic basis of cancer of the kidney. Kidney cancer is not a single disease. It is made up of a number of different types of cancer, each of which has a different histology, a different clinical course, which respond differently to therapy and are caused by different genes. Studies of the kidney cancer gene pathways have revealed that kidney cancer is fundamentally a metabolic disease.
The page was last updated on Thursday, February 1, 2018 - 12:41pm